349 results
Search Results
2. Update on 1-benzylpiperazine (BZP) party pills
3. Pharmacokinetics of levodopa
4. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back
5. Negative chronotropic and inotropic effects of class I antiarrhythmic drugs assessed in isolated canine blood-perfused sinoatrial node and papillary muscle preparations
6. Effect of BAY x7195, an oral receptor antagonist of cysteinyl-leukotrienes, on leukotriene D4-induced bronchoconstriction in normal volunteers
7. Clinical, pharmacokinetic and biological studies of topotecan
8. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations
9. Etoposide dosage and pharmacodynamics
10. A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer
11. Pharmacokinetic and pharmacodynamic data and models in clinical trials
12. Benzodiazepine pharmacodynamics: evidence for biophase rate limiting mechanisms
13. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam
14. A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens
15. Medikamentöse Therapie bei Frauen – Was gilt es zu beachten?
16. Strategien zur Vermeidung von Antibiotikaresistenzen
17. Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination
18. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
19. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects
20. Fluoxetine pharmacogenetics in child and adult populations
21. Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects
22. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension
23. An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects
24. Entry-into-humans study with a new direct renin inhibitor
25. Pharmakotherapie im Alter aus internistisch-pneumologischer Sicht
26. Exposure–Response Relationship of the Synthetic Epothilone Sagopilone in a Peripheral Neurotoxicity Rat Model
27. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients
28. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
29. Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid
30. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
31. Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts
32. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
33. Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes
34. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis
35. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial
36. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects
37. Antimikrobielle Therapie bei Patienten nach Verbrennungstrauma
38. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects
39. Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation
40. Characterisation of the iterative integral parameter identification method
41. Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation
42. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
43. Macitentan: entry-into-humans study with a new endothelin receptor antagonist
44. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats
45. A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics
46. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
47. Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
48. The role of population PK–PD modelling in paediatric clinical research
49. Endpoints in pediatric pain studies
50. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.